Financials data is unavailable for this security.
View more
Year on year Ensysce Biosciences Inc had revenues fall -11.61% from 2.52m to 2.23m, though the company grew net income from a loss of 24.17m to a smaller loss of 10.61m.
| Gross margin | -- |
|---|---|
| Net profit margin | -784.43% |
| Operating margin | -671.90% |
| Return on assets | -246.46% |
|---|---|
| Return on equity | -380.59% |
| Return on investment | -376.98% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Ensysce Biosciences Inc fell by 2.02m. Cash Flow from Financing totalled 8.76m or 392.55% of revenues. In addition the company used 10.78m for operations while cash from investing was breakeven.
| Cash flow per share | -2.23 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.2218 |
|---|---|
| Tangible book value per share | 0.2218 |
More ▼
Balance sheet in USDView more
| Current ratio | 1.88 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.2514 |
|---|---|
| Total debt/total capital | 0.235 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items increased 96.63%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 96.40 |
